SCHEMBL5700024

SCHEMBL5700024

Cc1ccc(OC(=O)c2ccccc2B(O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PTK2B Q14289 1/20 0.59
▸ RXFP1 Q9HBX9 1/20 0.59
▸ MAOA P21397 1/20 0.54
▸ MAOB P27338 1/20 0.54
▸ KMT2A Q03164 4/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ CYP1A2 P05177 2/20 0.48
▸ CYP2C19 P33261 2/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ LMNA P02545 3/20 0.47
▸ MAPT P10636 6/20 0.47
▸ GAA P10253 1/20 0.47
▸ HPGD P15428 2/20 0.47
▸ XBP1 P17861 1/20 0.47
▸ ALOX15 P16050 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30721723 0.88 HSD17B10 (0.59) PTK2BRXFP1KMT2ANPSR1MEN1
SCHEMBL208281 0.86 PTK2B (0.70) PTK2BRXFP1MAOAMAOBKMT2A
SCHEMBL8297882 0.84 HPGD (0.46) PTK2BRXFP1KMT2ANPSR1MEN1
SCHEMBL10983921 0.82 PTK2B (0.66) PTK2BRXFP1MAOAMAOBKMT2A
SCHEMBL8297749 0.81 MAPT (0.49) KMT2ANPSR1MEN1ALDH1A1CYP1A2
SCHEMBL14062702 0.81 KMT2A (0.65) PTK2BRXFP1MAOAMAOBKMT2A
SCHEMBL8297850 0.80 KMT2A (0.43) KMT2ANPSR1MEN1ALDH1A1CYP1A2
SCHEMBL29627754 0.79 PTK2B (0.62) PTK2BRXFP1MAOAMAOBKMT2A
SCHEMBL1603005 0.79 HSD17B10 (0.73) PTK2BRXFP1MAOAMAOBKMT2A
SCHEMBL4624103 0.79 KDM4E (0.50) PTK2BKMT2AMEN1ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1270582-B1 TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES MITSUBISHI RAYON CO (JP) 2006-08-30 — — EP disclosed
US-6693210-B2 USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS MITSUBISHI RAYON CO., LTD. (JP) 2004-02-17 — — US disclosed
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts MITSUBISHI RAYON CO., LTD. (JP) 2003-04-03 — — US disclosed
EP-1270582-A1 TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE Mitsubishi Rayon Co., Ltd. (JP) 2003-01-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts PDCD1LG2, PIK3CA, PDCD1 PTK2B 1019/4885RXFP1 4885/4885MAOA 4163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback